CGM for Management of Type 2 Diabetes in Pregnancy
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Oct 3, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether continuous glucose monitoring (CGM) is more effective than the traditional method of checking blood sugar levels with fingersticks for managing type 2 diabetes during pregnancy. The study aims to find out if using CGM helps improve the health outcomes of both mothers and their babies. It will also look at other factors that might increase the risk of complications for both mothers and infants in pregnancies complicated by type 2 diabetes.
To participate in this trial, women aged 18 to 50 who have type 2 diabetes and are pregnant with a viable fetus between 6 and 23 weeks of gestation may be eligible. Throughout the study, participants will either use CGM or continue with fingerstick monitoring until delivery. They will also provide blood samples at different stages of pregnancy and complete surveys about their support systems and feelings related to diabetes management. Additionally, umbilical cord blood will be collected at delivery for further research. This trial is not yet recruiting participants, but it represents an important step in understanding how to better manage diabetes in pregnancy for improved outcomes.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater
- • Pregnant with viable fetus at 6 to less than 23 weeks gestation
- • Maternal age 18-50 years old
- Exclusion Criteria:
- • Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions
- • Multiple gestation
- • Major fetal anomaly or two or more minor fetal anomalies
- • Planned delivery outside study consortium
- • Participating in another conflicting interventional study
- • Participation in this trial in a previous pregnancy
- • Patient unable to consent
- • Physician refusal for other reasons
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Birmingham, Alabama, United States
Houston, Texas, United States
Chapel Hill, North Carolina, United States
Greenville, South Carolina, United States
San Diego, California, United States
Portland, Oregon, United States
Patients applied
Trial Officials
Ashley Battarbee, MD, MSCR
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported